Novartis AG is a global healthcare company that specializes in developing and manufacturing innovative pharmaceuticals and medical products. The company focuses on research-driven solutions in various therapeutic areas, including oncology, cardiology, immunology, and neuroscience, among others. Novartis is committed to improving patient health by providing high-quality medications and treatments, and it invests significantly in research and development to discover and deliver new therapies. In addition to its pharmaceutical division, Novartis also offers generics and biosimilars through its Sandoz division, making healthcare more accessible to patients worldwide. Read More
BioMedWire Editorial Coverage: Today’s multiple sclerosis treatments can slow down disease progression, but none of them halt it outright, and none give back the function patients have already lost. Close to a million people in the United States, and nearly 2.9 million worldwide, live with that reality, watching a condition that steadily chips away at mobility, eyesight and basic physical control. That gap in treatment options just picked up a serious new contender. Quantum BioPharma Ltd. (NASDAQ: QNTM) ( Profile ) has received U.S. Food and Drug Administration (“FDA”) clearance to launch a phase 2 trial of Lucid-MS, a patented, first-in-class candidate designed not to calm the immune system but to shield, and potentially rebuild, the myelin sheath itself. The clearance sets up what would be the first time in history that a drug built on this exact mechanism gets tested in people living with MS, a milestone significant enough that it has already drawn a fresh buy rating from Wall Street analysts. That momentum puts Quantum BioPharma squarely among a group of leading pharma companies, including Novartis AG (NYSE: NVS), Merck & Co. Inc. (NYSE: MRK), TG Therapeutics Inc. (NASDAQ: TGTX) and Bristol-Myers Squibb Company (NYSE: BMY), that are focused on treating serious diseases and areas of major…
AUSTIN, Texas, Sept. 10, 2026 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage: Today's multiple sclerosis treatments can slow down disease progression, but none of them halt it outright, and none give back the function patients have already lost. Close to a million people in the United States, and nearly 2.9 million worldwide, live with that reality, watching a condition that steadily chips away at mobility, eyesight and basic physical control. That gap in treatment options just picked up a serious new contender. Quantum BioPharma Ltd. (NASDAQ: QNTM) (profile) has received U.S. Food and Drug Administration (“FDA”) clearance to launch a phase 2 trial of Lucid-MS, a patented, first-in-class candidate designed not to calm the immune system but to shield, and potentially rebuild, the myelin sheath itself. The clearance sets up what would be the first time in history that a drug built on this exact mechanism gets tested in people living with MS, a milestone significant enough that it has already drawn a fresh buy rating from Wall Street analysts. That momentum puts Quantum BioPharma squarely among a group of leading pharma companies, including Novartis AG (NYSE: NVS), Merck & Co. Inc. (NYSE: MRK), TG Therapeutics Inc. (NASDAQ: TGTX) and Bristol-Myers Squibb Company (NYSE: BMY), that are focused on treating serious diseases and areas of major unmet medical need.
(Novartis) - Dr. Koo, EVP and CMO at Prostate Cancer Foundation, and Bill, who is living with prostate cancer, answer some frequently asked questions about PSMA testing. Talk to your doctor and visit GetYourScan.com. Sponsored by Novartis
Vanguard offers three dividend ETFs—VIG, VYM, and VYMI—with distinct yields, holdings, and geographic focus, giving income investors varied ways to access dividend-paying stocks.
The JPMorgan International Value ETF (JIVE) has outpaced the S&P 500 this year, offering low-volatility, diversified international exposure with a 1.22% yield and rising institutional demand.
